Hdl Handle:
http://hdl.handle.net/10147/253999
Title:
Medical therapy in acromegaly.
Authors:
Sherlock, Mark; Woods, Conor; Sheppard, Michael C
Affiliation:
Centre for Endocrinology Diabetes and Metabolism, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Citation:
Medical therapy in acromegaly. 2011, 7 (5):291-300 Nat Rev Endocrinol
Publisher:
Nature reviews. Endocrinology
Journal:
Nature reviews. Endocrinology
Issue Date:
May-2011
URI:
http://hdl.handle.net/10147/253999
DOI:
10.1038/nrendo.2011.42
PubMed ID:
21448141
Abstract:
Acromegaly is a rare disease characterized by excess secretion of growth hormone (GH) and increased circulating insulin-like growth factor 1 (IGF-1) concentrations. The disease is associated with increased morbidity and premature mortality, but these effects can be reduced if GH levels are decreased to <2.5 μg/l and IGF-1 levels are normalized. Therapy for acromegaly is targeted at decreasing GH and IGF-1 levels, ameliorating patients' symptoms and decreasing any local compressive effects of the pituitary adenoma. The therapeutic options for acromegaly include surgery, radiotherapy and medical therapies, such as dopamine agonists, somatostatin receptor ligands and the GH receptor antagonist pegvisomant. Medical therapy is currently most widely used as secondary treatment for persistent or recurrent acromegaly following noncurative surgery, although it is increasingly used as primary therapy. This Review provides an overview of current and future pharmacological therapies for patients with acromegaly.
Item Type:
Article
Language:
en
MeSH:
Acromegaly; Dopamine Agonists; Human Growth Hormone; Humans; Insulin-Like Growth Factor I
ISSN:
1759-5037

Full metadata record

DC FieldValue Language
dc.contributor.authorSherlock, Marken_GB
dc.contributor.authorWoods, Conoren_GB
dc.contributor.authorSheppard, Michael Cen_GB
dc.date.accessioned2012-11-29T15:28:30Z-
dc.date.available2012-11-29T15:28:30Z-
dc.date.issued2011-05-
dc.identifier.citationMedical therapy in acromegaly. 2011, 7 (5):291-300 Nat Rev Endocrinolen_GB
dc.identifier.issn1759-5037-
dc.identifier.pmid21448141-
dc.identifier.doi10.1038/nrendo.2011.42-
dc.identifier.urihttp://hdl.handle.net/10147/253999-
dc.description.abstractAcromegaly is a rare disease characterized by excess secretion of growth hormone (GH) and increased circulating insulin-like growth factor 1 (IGF-1) concentrations. The disease is associated with increased morbidity and premature mortality, but these effects can be reduced if GH levels are decreased to <2.5 μg/l and IGF-1 levels are normalized. Therapy for acromegaly is targeted at decreasing GH and IGF-1 levels, ameliorating patients' symptoms and decreasing any local compressive effects of the pituitary adenoma. The therapeutic options for acromegaly include surgery, radiotherapy and medical therapies, such as dopamine agonists, somatostatin receptor ligands and the GH receptor antagonist pegvisomant. Medical therapy is currently most widely used as secondary treatment for persistent or recurrent acromegaly following noncurative surgery, although it is increasingly used as primary therapy. This Review provides an overview of current and future pharmacological therapies for patients with acromegaly.en_GB
dc.language.isoenen
dc.publisherNature reviews. Endocrinologyen_GB
dc.rightsArchived with thanks to Nature reviews. Endocrinologyen_GB
dc.subject.meshAcromegaly-
dc.subject.meshDopamine Agonists-
dc.subject.meshHuman Growth Hormone-
dc.subject.meshHumans-
dc.subject.meshInsulin-Like Growth Factor I-
dc.titleMedical therapy in acromegaly.en_GB
dc.typeArticleen
dc.contributor.departmentCentre for Endocrinology Diabetes and Metabolism, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.en_GB
dc.identifier.journalNature reviews. Endocrinologyen_GB
dc.description.provinceLeinsteren

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.